EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Cytomegalovirus prophylaxis with letermovir in pediatric (birth to

Andreas H Groll iD, Lara Danziger-Isakov, Aharon Gefen, Christopher J Fraser, Johannes H Schulte, Bella Bielorai, Nicole A Karras, David Bueno, Peter J Shaw, Natalya Broyde, Barbara Haber, Christopher L Gilbert und 3 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00420-25 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Andreas H Groll und 14 weiteren Autor:innen. Beteiligte Einrichtung: University Children's Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Acetates, Antiviral Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Letermovir, a cytomegalovirus (CMV) terminase complex inhibitor, was first approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic cell transplant (HCT) recipients (R+). This study evaluated the pharmacokinetics (PK), efficacy, and safety of letermovir in pediatric R+ allogeneic HCT recipients. In this Phase 2b, single-arm, open-label study, 65 participants were enrolled sequentially in three age groups (AG; AG1, 12 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsAcetatesAntiviral AgentsQuinazolinesHumansChildFemaleMaleChild, PreschoolAdolescentInfantCytomegalovirusInfant, NewbornAdult

Stichwörter der Autor:innen

cytomegalovirushematopoietic cell transplantationletermovirpediatricpharmacokinetics

Substanzen

letermovirAcetatesAntiviral AgentsQuinazolines

Autor:innen und Institutionen

  • University Children's Hospital Münster, Münster, Germany.
  • Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
  • Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
  • Queensland Children's Hospital, Brisbane, Queensland, Australia.
  • Charité Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Andreas H Groll

Förderung

  • Merck Sharp & Dohme LLC

Zitieren

APA

Groll, A. H., Danziger-Isakov, L., Gefen, A., Fraser, C. J., Schulte, J. H., Bielorai, B., Karras, N. A., Bueno, D., Shaw, P. J., Broyde, N., Haber, B., Gilbert, C. L., Patel, M., McCrea, J. B., & Badshah, C. (2025). Cytomegalovirus prophylaxis with letermovir in pediatric (birth to. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00420-25

Vancouver

Groll AH, Danziger-Isakov L, Gefen A, Fraser CJ, Schulte JH, Bielorai B, et al. Cytomegalovirus prophylaxis with letermovir in pediatric (birth to. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00420-25

BibTeX
@article{Groll2025,
  author = {Groll, Andreas H and Danziger-Isakov, Lara and Gefen, Aharon and Fraser, Christopher J and Schulte, Johannes H and Bielorai, Bella and Karras, Nicole A and Bueno, David and Shaw, Peter J and Broyde, Natalya and Haber, Barbara and Gilbert, Christopher L and Patel, Mayankbhai and McCrea, Jacqueline B and Badshah, Cyrus},
  title = {Cytomegalovirus prophylaxis with letermovir in pediatric (birth to},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00420-25}
}
Kostenlos starten →